141 related articles for article (PubMed ID: 34791927)
1. Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature.
Liu L; Brown EN; Abu-Shahin FI
J Oncol Pharm Pract; 2022 Apr; 28(3):703-709. PubMed ID: 34791927
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine-induced acute toxic leukoencephalopathy.
Obadia M; Leclercq D; Wasserman J; Galanaud D; Dormont D; Sahli-Amor M; Psimaras D; Pyatigorskaya N; Law-Ye B
Neurotoxicology; 2017 Sep; 62():1-5. PubMed ID: 28487252
[TBL] [Abstract][Full Text] [Related]
3. [Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer].
Yasaki S; Tukamoto Y; Yuasa N; Ishikawa T; Yoshii F
Rinsho Shinkeigaku; 2012; 52(4):251-6. PubMed ID: 22531658
[TBL] [Abstract][Full Text] [Related]
4. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Beyerlin K; Jimenez R; Zangardi M; Fell GG; Edmonds C; Johnson A; Bossuyt V; Specht M; Mulvey TM; Moy B; Ellisen LW; Isakoff SJ; Bardia A; Spring LM
J Oncol Pharm Pract; 2021 Dec; 27(8):1883-1890. PubMed ID: 33153384
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
Endo A; Yoshida Y; Nakashima R; Takahashi N; Tanabe K
Int Heart J; 2013; 54(6):417-20. PubMed ID: 24309454
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
de Boo LW; Jóźwiak K; Joensuu H; Lindman H; Lauttia S; Opdam M; van Steenis C; Brugman W; Kluin RJC; Schouten PC; Kok M; Nederlof PM; Hauptmann M; Linn SC
Br J Cancer; 2022 Jun; 126(10):1401-1409. PubMed ID: 35124703
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Lee A; Go SI; Lee WS; Lee US; Kim MJ; Kang MH; Lee GW; Kim HG; Kang JH; Jeon KN; Cho JM; Lee JH
Tumori; 2015 Mar; 101(1):e9-e12. PubMed ID: 25702650
[TBL] [Abstract][Full Text] [Related]
10. Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine.
Perrain V; Bihan K; Bompaire F; Houillier C; Jomier F; Leclercq D; Combret S; Mahé J; Ricard D; Berzero G; Psimaras D
Eur J Neurol; 2021 Jul; 28(7):2396-2402. PubMed ID: 33817933
[TBL] [Abstract][Full Text] [Related]
11. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.
Laird J; Leventhal J; Kanowitz J; Damast S
Pract Radiat Oncol; 2021; 11(6):448-452. PubMed ID: 34157449
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
Guven DC; Taban H; Dizdar O
J Oncol Pharm Pract; 2022 Jan; 28(1):203-204. PubMed ID: 34628993
[No Abstract] [Full Text] [Related]
13. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X; Wang SS; Huang H; Cai L; Zhao L; Peng RJ; Lin Y; Tang J; Zeng J; Zhang LH; Ke YL; Wang XM; Liu XM; Chen QJ; Zhang AQ; Xu F; Bi XW; Huang JJ; Li JB; Pang DM; Xue C; Shi YX; He ZY; Lin HX; An X; Xia W; Cao Y; Guo Y; Su YH; Hua X; Wang XY; Hong RX; Jiang KK; Song CG; Huang ZZ; Shi W; Zhong YY; Yuan ZY;
JAMA; 2021 Jan; 325(1):50-58. PubMed ID: 33300950
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Mokrim M; Aftimos PG; Errihani H; Piccart-Gebhart M
BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24748142
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine-related neurotoxicity presenting with agraphia.
Iscan D; Tolay R; Bayram E; Demir T; Bicakci S
J Oncol Pharm Pract; 2023 Apr; 29(3):746-749. PubMed ID: 35903929
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine induced fingerprint loss: Case report and review of the literature.
Deneken-Hernandez Z; Cherem-Kibrit M; Gutiérrez-Andrade L; Rodríguez-Gutiérrez G; Colmenero-Mercado JO
J Oncol Pharm Pract; 2022 Mar; 28(2):495-499. PubMed ID: 34609922
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
19. Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Asleh K; Brauer HA; Sullivan A; Lauttia S; Lindman H; Nielsen TO; Joensuu H; Thompson EA; Chumsri S
Clin Cancer Res; 2020 Jun; 26(11):2603-2614. PubMed ID: 32005747
[TBL] [Abstract][Full Text] [Related]
20. Posterior reversible encephalopathy syndrome: A rare neurotoxicity after capecitabine.
Monti M; Barone D; Amadori E; Bartolini G; Ruscelli S; Frassineti GL
J Oncol Pharm Pract; 2020 Oct; 26(7):1795-1801. PubMed ID: 32312144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
